Zydus Cadila has received approval from USFDA to market mesalamine tablets used for the treatment of ulcerative colitis. The US FDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market. The drug is generic version of Lialda (mesalamine). Now, the company will manufacture the product at its Moraiya facility in Ahmedabad.
Company Profile : Cadila Healthcare Ltd
Leave a Reply